Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues
serve people in more than 160 countries. At Abbott, we believe people with diabetes should enjoy active lives, so we’re focused on making breakthrough technology accessible and approachable for all. Our groundbreaking sensing technology is revolutionising how people monitor glucose and providing healthcare professionals with more data to make better informed treatment decisions.

www.FreeStyleDiabetes.co.uk
www.FreeStyleLibre.co.uk

At Dexcom, we believe that with Diabetes, knowledge is power, we’ve spent the last 20 years innovating and developing simpler and better ways for people with type 1 diabetes
to measure, track and manage their diabetes. When Dexcom was established the only way to measure glucose levels was to fingerstick, it gave us a snapshot not a story
which made it difficult to understand our glucose levels and trends over time or feel in control of our diabetes. Since then, we’ve launched the world’s fi rst real-time CGM system and helped to eliminate more than 11 billion fingersticks.

www.dexcom.com

At Colonis, we repurpose medicines to make them more manageable for patients. By identifying and understanding how unmet clinical needs impact patients, we develop
innovative solutions that improve compliance and enhance health outcomes, empowering individuals to live their lives to the fullest. Our mission is to support patients in receiving the most appropriate and accessible treatment for a better quality of life.

www.colonis.co.uk

Neurocrine Biosciences and Diurnal have united to develop therapeutics for people living with rare and chronic endocrine conditions. Together, through our deep neuroendocrinology knowledge and proven clinical development expertise, we are
advancing therapies for adrenal insufficiency and for congenital adrenal hyperplasia. Find out more at our Stand during the Congress.

www.diurnal.com

Inozyme Pharma is a rare disease
biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal
proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic
diseases associated with significant morbidity, mortality, and unmet medical need. Please get in touch if you encounter potential subjects for our clinical trials program.

www.inozyme.com

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative totraditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or
handle a needle. Insulet’s latest innovation, the Omnipod©5 Automated Insulin Delivery
system, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with
no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

www.insulet.com
www.omnipod.com

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop
technologies that improve and enhance life, in biopharmaceuticals, developing therapies to treat cancer, multiple sclerosis, and endocrine
conditions.

In endocrinology, Merck has established
treatments in diabetes and growth hormone replacement, treating thousands of patients in the UK. With growth hormone therapy we
are enhancing our digital tools in line with NHS Digital transformation plan and are committed to meeting patients’ and healthcare
professionals’ evolving needs.

In recent years Merck has launched a new digital ecosystem, to support patients and healthcare professionals to optimise growth
hormone treatment. This was enhanced in 2023 with the launch of a new easypod® injection device, offering significant use advantages over previous devices. These digital solutions are integrated into nurse led MySupport training and digital patient support
program.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our
heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 69,000 people in 80 countries and markets its products in around 170 countries.

www.novonordisk.co.uk

PC PAL is the specialist developer of digital growth charting software – notably GrowthXP – used in 20% of the 100 best hospitals in the
world. This application off ers integration with electronic health records, charts for over 50 rare disorders (e.g. achondroplasia, Noonan, Prader-Willi, Down and Turner), multiple curves,
calculations displayed automatically (e.g. target height, height velocity, bone age delay) and
a comprehensive set of charts customized for local populations. We work closely with specialists to refi ne GrowthXP in response to changing clinicians needs, with a current
focus on BMI in order to improve the charting of severe obesity in children and adolescents.
Please visit our booth to discuss your needs and to test drive GrowthXP.

www.pcpal.eu

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and
manufacture of healthcare products, including innovative medicines and vaccines. To learn more about our commitments, please visit our website.

www.pfizer.co.uk

Sandoz is a global leader in generic

pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing affordable approaches that address unmet
medical needs. Our ambition is to be the world’s leading generics company and our broad portfolio of high-quality medicines covers major therapeutic areas.

www.sandoz.uk.com

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed
to transforming the care for patients living with rare genetic diseases of obesity. For more information, please contact Fleur Taylor at [email protected]

www.rhythmtx.com

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially
life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

www.sanofi.co.uk

Dedicated to ensuring today’s advanced
therapies enable healthier lives tomorrow. Founded in 2021, Tetris Pharma is focused on the registration, marketing, sales, and
distribution of specialty products in the UK and Europe. We are a pharmaceutical company
and a subsidiary of Arecor Therapeutics plc. We collaborate with partners across Europe to provide patients with effective treatments and quality healthcare by ensuring accountability,
dedication and performance.

www.tetrispharma.com